Trial Profile
A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan (Primary) ; Prednisone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms RP_MPR
- 28 Jun 2023 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 22 Dec 2020 Planned End Date changed from 1 Aug 2020 to 1 Dec 2021.